Cor Vasa 2010, 52(3):168-175 | DOI: 10.33678/cor.2010.044

BARI 2D - where has it taken us to and what the future has in store for us

Lenka Pavlíčková*, Petr Neužil
Kardiologické oddělení, Kardiocentrum, Nemocnice Na Homolce, Praha, Česká republika

Background: Optimal therapy for diabetics with stable coronary artery disease and mild symptoms has not yet been established. The BARI 2D study is the successor to the BARI study where diabetics (especially those on insulin) had a worse long-term outcome after revascularization compared with other populations. The multicenter clinical BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Study took place from 2001-2008. It compared early revascularization (ER - either PCI or CABG) with medical therapy (MT), together with intensive pharmacotherapy and lifestyle intervention in both groups. At the same time, two diabetes drug treatment strategies ("insulin sensitizers" - ISs and "insulin providers" - IPs) were compared. The primary endpoint was 5-year all-cause mortality.

Methods: A total of 2 368 patients with type-2 diabetes with stable coronary artery disease suitable for revascularization (with the choice of actual intervention dependent on the cardiologist) were randomized to either ER or MT. Simultaneously, independent randomization to either IS or IP diabetes treatment was performed. The average follow-up period was 5.3 years.

Results: Overall 5-year mortality was 11.7% (n = 137) in the ER group vs. 12.2% (n = 145) in the MT group (p = 0.97, n.s.) and 11.8% (n = 139) in the IS group vs. 12.1% (n = 143) in the IP group, (p = 0.89, n.s.). The secondary composite endpoint (death + nonfatal myocardial infarction + stroke) findings were also not statistically significant: ER 22.8% (n = 268) vs. MT 24.1% (n = 287), p = 0.70, and IS 22.3% (n = 264) vs. IP 24.6% (n = 291), p = 0.13; subgroup analysis showed that the rate of major cardiovascular (CV) events in those scheduled for CABG was significantly lower in the ER group than in the MT group (22.4% vs. 30.5%, p = 0.01).

Conclusion: None of the treatment strategies showed a clear benefit in terms of reducing mortality or major cardiovascular events - there was no significant difference between the initial revascularization group versus the medical therapy group, nor between the "insulin sensitization" versus the "insulin provision" groups. The only significant difference - fewer major CV events in the early revascularized patients scheduled for CABG - is probably related to the less severe coronary artery disease in these patients.

Keywords: Coronary artery disease; Diabetes mellitus; Revascularization; Conservative therapy

Published: March 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavlíčková L, Neužil P. BARI 2D - where has it taken us to and what the future has in store for us. Cor Vasa. 2010;52(3):168-175. doi: 10.33678/cor.2010.044.
Download citation

References

  1. BARI 2D Study Group, Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-2515. Go to original source... Go to PubMed...
  2. Diabetes Atlas third edition, International Diabetes Federation 2005: Preventing Chronic Diseases: a vital investment, WHO, 2005.
  3. Diabetes at a Glance 2009 - http://www.cdc.gov, American Diabetes Association - http://www.ada.com.
  4. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689. Go to original source...
  5. Lenzen MJ, Boersma E, Bertrand ME, et al. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J 2005;26:1169-1179. Go to original source... Go to PubMed...
  6. Ročenka ÚZIS 2008, http://www.uzis.cz.
  7. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc 2009;84:741-757. Go to original source...
  8. Mytas DZ, Stougiannos PN, Zairis MN, et al. Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. J Diabetes Complications 2009;23:273-282. Go to original source... Go to PubMed...
  9. Špinar J, Vítovec J. Metabolický syndrom a kardiovaskulární onemocnění. Vnitř Lék 2009; 55:653-658. Go to PubMed...
  10. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: Aubert RE, Ballard DJ, Barrett-Connor E, eds. Diabetes in America. 2nd ed. Bethesda, MD; National Institute of Diabetes and Digestive and Kidney Diseases, 1995:233-257.
  11. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997;30:171-179. Go to original source...
  12. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2009;102:1014-1019. Go to original source...
  13. Bonora E, Targher G, Formentini F, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona diabetes complication study. Diabet Med 2002;21:52. Go to original source...
  14. Cífková R, Býma S, Češka R, et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Vnitř Lék 2005;51:2021-2025.
  15. Depres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Eng J Med 1996;334:952-957. Go to original source...
  16. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393. Go to original source...
  17. Mannucci E, Monami M, Massotti G, Marchionni N. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 2004;20:44-47. Go to original source... Go to PubMed...
  18. BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1996;96:1761-1769. Go to original source...
  19. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996;335:275-277. Go to original source...
  20. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999;99:633-640. Go to original source...
  21. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591. Go to original source...
  22. Albu J, Gottlieb SH, August P, et al. Modifications of coronary risk factors. Am J Cardiol 2006;97(Suppl 12A):416-526. Go to original source... Go to PubMed...
  23. UK Prospective Diabetes Study. Papers presenting major results of the study. UKPDS 33 + 34: Lancet 1998;352:837-865. Go to original source...
  24. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119:351-357. Go to original source...
  25. Annaswamy R, Seely E, Bekins S, et al. Rosiglitazon improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26:172-178. Go to original source... Go to PubMed...
  26. Hafner SM, Mykkänen L, Festa A, et al. Insulin-resistant prediabetic subject have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during prediabetic state. Circulation 2000;101:975-980. Go to original source... Go to PubMed...
  27. Kronmal RA, Barzilay JI, Tracy RP, et al. The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. J Clin Endocrinol Metab 2004;89:2852-2858. Go to original source... Go to PubMed...
  28. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-1780. Go to original source... Go to PubMed...
  29. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471. Go to original source... Go to PubMed...
  30. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-1195. Go to original source... Go to PubMed...
  31. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 2009;373:911-918. Go to original source... Go to PubMed...
  32. Roger S, Blumenthal RS, Cohn G, Schulman SP. Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature. J Am Coll Cardiol 2000;36:668-673. Go to original source... Go to PubMed...
  33. Duckworth W, Abraira C, Mortiy T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139. Go to original source... Go to PubMed...
  34. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood sugar control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572. Go to original source... Go to PubMed...
  35. Action to Control Cardiovascular risk in Diabetes Study group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559. Go to original source... Go to PubMed...
  36. Hoffman SN, TenBrook JA, Wolf MP, et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 2003;41:1293-1304. Go to original source...
  37. Lagerqvist B, Husted S, Kontny F, et al. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet 2006;368:998-1004. Go to original source...
  38. RITA-2 trial participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997;350:461-468.
  39. Boden WE, et al., for the COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516. Go to original source...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.